AstraZeneca PLC (AZN) - Stock Analysis
Last updated: Mar 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Recent high-impact drug catalysts (ENHERTU new 1L breast cancer approval, Baxdrostat NDA Priority Review) plus reiterated 2026 growth guidance and a ~19% 21-day price run with shares ~9% above the 21-day SMA and breaking out of the 188â195 range support near-term continuation for a disciplined momentum trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High margins ⢠Robust FCF ⢠Heavy R&D spend AZN delivers strong profitability and free cash flow that fund dividends and heavy R&D-backed intangible value, but faces tight near-term liquidity and rich valuation multiples.
Price Behavior
Key Price Behavior Insights: ⢠Below last-month SMA ⢠~7% pullback ⢠Resistance band tested Support Level: $185â$186 Resistance Level: $206â$208 AZN is in a mild short-term downtrend, trading below its last-month SMA (~$200.7) after a ~6.9% pullback from the lateâFeb $208.45 peak to $194.22, with $206â$208 resistance and $185â$186 support the key momentum triggers.
Sentiment & News
Key News Insights: ⢠Raised guidance ⢠Institutional buying ⢠Pipeline-driven growth AstraZeneca showed strong commercial momentum, bullish analyst support and institutional buying after raising guidance and a dividend despite a mixed Q4 print and patent-timing risks tied to its oncology-driven $80bn-by-2030 ambition.
AI Summary
AstraZeneca should be viewed as an aggressive, pipelineâdriven growth investment (not a defensive yield play) where upside depends on multiple 2026 Phaseâ3 readouts and ENHERTU commercialization offsetting nearâterm margin dilution from elevated R&D and capex. Monitor the 2026 readout calendar, ENHERTU combo uptake, and U.S. manufacturing execution closelyâfailures or execution delays would likely trigger a sharp valuation reârating.
Description
AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacture and commercialization of prescription medicines across oncology, cardiovascular, renal and metabolic (CVRM), respiratory, vaccines and rare diseases. Its commercial portfolio and pipeline span established brands and newer therapies for core therapeutic areas, and the company distributes products through primary and specialty care channels across the UK, Europe, the Americas, Asia, Africa and Australasia. Incorporated in 1992 and headquartered in Cambridge, UK, AstraZeneca maintains external R&D collaborations with partners such as Neurimmune AG, BenevolentAI, Lunit and Absci Corporation.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 20 | Feb 27 | AZN | AstraZeneca PLC | Recent high-impact drug catalysts (ENHERTU new 1L breast cancer approval, Baxdrostat NDA Priority Review) plus reiterated 2026 growth guidance and a ~19% 21-day price run with shares ~9% above the 21-day SMA and breaking out of the 188â195 range support near-term continuation for a disciplined momentum trade. | Closed | +2.1% |